RPA3A Antibody

What are the recommended applications for RPA3 antibody?

RPA3 antibody (10692-1-AP) has been validated for several key applications in molecular and cellular research. Based on extensive testing, this antibody shows consistent performance in Western Blot (WB), Immunohistochemistry (IHC), and ELISA applications with human samples . Positive Western Blot detection has been confirmed in multiple cell lines including K-562, Jurkat, A549, HeLa, and HepG2 cells, demonstrating its broad utility across different human cell types . For immunohistochemistry, the antibody has been specifically validated with human lung cancer tissue .

What are the optimal dilution ratios for different experimental applications?

Proper antibody dilution is critical for obtaining reliable results while conserving reagents. For RPA3 antibody (10692-1-AP), the following dilution ranges have been experimentally determined:

It is important to note that these ranges serve as starting points and the antibody should be titrated in each specific testing system to achieve optimal results, as sensitivity can be sample-dependent .

How should RPA3 antibody be stored to maintain optimal activity?

Proper storage is essential for maintaining antibody efficacy. The RPA3 antibody should be stored at -20°C, where it remains stable for one year after shipment . The antibody is provided in PBS buffer containing 0.02% sodium azide and 50% glycerol at pH 7.3 . For the 20μl size, the formulation contains 0.1% BSA . Importantly, aliquoting is unnecessary for -20°C storage, which simplifies laboratory handling procedures .

What antigen retrieval methods are recommended for IHC applications with RPA3 antibody?

For immunohistochemistry applications, effective antigen retrieval is crucial for optimal staining. With RPA3 antibody (10692-1-AP), the primary suggested method is antigen retrieval with TE buffer at pH 9.0 . As an alternative approach, citrate buffer at pH 6.0 may also be used for antigen retrieval . These specific buffer conditions have been validated to expose the appropriate epitopes while maintaining tissue morphology, enabling consistent and reproducible immunohistochemical detection of RPA3.

How can single experimental subject designs improve RPA3 antibody validation across diverse genetic backgrounds?

Traditional experimental designs typically employ multiple subjects per treatment group, limiting the genetic diversity that can be represented within a study. Adopting a single mouse experimental design approach, as demonstrated in recent preclinical studies, allows researchers to encompass greater genetic diversity when validating antibodies like RPA3 .

In a paradigm-shifting analysis of Pediatric Preclinical Testing Program (PPTP) data, researchers found that designs using one mouse per treatment group yielded results comparable to conventional 10-mice groups in approximately 80% of experiments . When allowing for minor interpretation differences, this equivalence increased to about 95% . This approach has significant implications for RPA3 antibody validation across genetically diverse cancer models, potentially improving translation to human applications.

The single-subject methodology effectively increases the number of testable models twenty-fold (from conventional 10+10 mice in control and treatment groups to 20 different models) . For RPA3 antibody validation, this allows testing across multiple cancer types with diverse genetic backgrounds, potentially identifying specific contexts where the antibody performs optimally or suboptimally.

What molecular weight variations of RPA3 might be detected and what do they signify?

When using RPA3 antibody in Western Blot applications, researchers should be aware of potential variations between calculated and observed molecular weights. The calculated molecular weight of RPA3 is 13 kDa, while the commonly observed molecular weight in experimental settings is 14 kDa . This slight discrepancy may be attributed to post-translational modifications or protein folding characteristics.

Researchers should use this information when interpreting Western Blot results, particularly when:

• Validating antibody specificity

• Investigating potential post-translational modifications of RPA3

• Comparing results across different experimental conditions that might affect protein processing

The consistent observation of a 14 kDa band serves as a quality control indicator for proper antibody function and experimental technique.

How can RPA3 antibody be utilized in DNA damage response pathway investigations?

RPA3 antibody provides a valuable tool for investigating DNA damage response pathways, particularly in contexts involving TP53 and 53BP1 mutations. Recent research indicates that mutations in 53BP1 were observed in 3 of 6 sensitive tumor models compared to none in resistant models . This suggests that RPA3 detection via immunoblotting or immunohistochemistry may serve as an important readout when characterizing DNA damage response defects.

The correlation between DNA damage response factors and tumor sensitivity suggests that RPA3 antibody could be particularly valuable in studies focused on:

• Characterizing mechanisms of DNA repair pathway defects

• Identifying potential biomarkers for therapeutic response

• Investigating synthetic lethality approaches targeting cells with specific DNA repair deficiencies

When designing such experiments, researchers should consider including appropriate controls that represent both wild-type TP53 and mutant TP53 with 53BP1 defects to provide context for RPA3 expression patterns .

What considerations should be made when interpreting contradictory RPA3 detection results across different cell lines?

When RPA3 antibody produces varying results across different cell lines, researchers should systematically evaluate several factors:

• Cell line-specific protein expression levels: RPA3 expression may naturally vary between cell types. The antibody has been positively validated in K-562, Jurkat, A549, HeLa, and HepG2 cells , providing a baseline for comparison.

• Protocol optimization requirements: Different cell lines may require modified lysis conditions, buffer compositions, or blocking agents to minimize background and maximize specific signal.

• Post-translational modifications: Cell type-specific phosphorylation, ubiquitination, or other modifications may affect epitope accessibility.

• Protein complex formation: RPA3 functions as part of the RPA complex, and its detection might be influenced by interaction partners that vary between cell types.

When encountering contradictory results, researchers should compare their findings with the validated cell lines reported in the literature and consider whether genetic background differences (such as TP53 or 53BP1 status) might explain the disparities .

How can RPA3 antibody be incorporated into multiplexed immunoassays for comprehensive pathway analysis?

Integrating RPA3 antibody into multiplexed immunoassays requires careful consideration of several technical factors:

• Antibody cross-reactivity assessment: Before multiplexing, validate that the RPA3 antibody (10692-1-AP) does not cross-react with other targets in your panel. The antibody's specificity for human samples should be verified in the specific experimental context .

• Compatible detection systems: When designing multiplexed fluorescent or chromogenic detection systems, ensure that secondary antibodies or detection reagents for RPA3 are compatible with other components in terms of species reactivity and emission/absorption spectra.

• Sequential staining protocols: For IHC applications, consider whether sequential staining rather than simultaneous staining would reduce potential cross-reactivity, particularly when using the recommended antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0) .

• Internal controls: Include appropriate positive controls (such as K-562 cells for Western Blot applications) to ensure that the multiplexed assay maintains sensitivity for RPA3 detection.

• Signal normalization: Develop appropriate normalization strategies to account for variation in staining intensity across different antibodies in the multiplex panel.

This comprehensive approach enables researchers to simultaneously analyze RPA3 alongside other proteins in complex pathways, providing deeper insights into the functional relationships between DNA replication, repair, and related cellular processes.

What controls are essential when using RPA3 antibody in comparative studies?

When designing experiments using RPA3 antibody for comparative studies across different conditions or samples, several controls are critical:

• Positive cellular controls: Include K-562, Jurkat, A549, HeLa, or HepG2 cells as positive controls for Western Blot applications, as these have been validated with the RPA3 antibody .

• Loading controls: For Western Blot quantification, appropriate loading controls (such as GAPDH or β-actin) should be used to normalize RPA3 signal intensity.

• Negative controls: Include samples known to express minimal or no RPA3, or use primary antibody omission controls to assess non-specific binding of secondary antibodies.

• Dilution series: Run a dilution series of your positive control to establish the linear range of detection for quantitative comparisons.

• Technical replicates: Include technical replicates to account for variability in antibody performance, particularly when working at the recommended dilution ranges of 1:500-1:2000 for WB and 1:750-1:3000 for IHC .

These controls ensure that any observed differences in RPA3 expression or localization can be confidently attributed to biological variation rather than technical artifacts.

How should researchers approach RPA3 antibody validation in novel cellular or tissue models?

When extending RPA3 antibody use to novel cellular or tissue models beyond the validated examples, researchers should implement a systematic validation approach:

• Cross-species reactivity assessment: While the antibody has been primarily validated in human samples , researchers working with other species should first confirm cross-reactivity using positive control human samples alongside the new species.

• Optimization of sample preparation: For new tissue types, modify fixation protocols and test both recommended antigen retrieval methods (TE buffer pH 9.0 and citrate buffer pH 6.0) to determine optimal conditions.

• Antibody titration: Even within the recommended dilution ranges, perform a titration specific to the new model to identify the optimal antibody concentration that maximizes signal-to-noise ratio.

• Correlation with orthogonal methods: Validate antibody specificity by correlating immunostaining patterns with RPA3 mRNA expression data or with results from alternative antibody clones.

• Knockout/knockdown controls: Where possible, include RPA3 knockout or knockdown samples as definitive negative controls to confirm antibody specificity in the new model.

This methodical validation approach ensures reliable and reproducible results when extending RPA3 antibody applications to previously untested experimental systems.

What are the most common causes of false positive or negative results with RPA3 antibody?

Understanding potential sources of error is critical for accurate data interpretation when working with RPA3 antibody:

Causes of false positive results:

• Insufficient blocking leading to non-specific binding

• Cross-reactivity with structurally similar proteins

• Overly concentrated primary or secondary antibody

• Inadequate washing steps between antibody incubations

• Endogenous peroxidase activity in IHC applications if not properly quenched

Causes of false negative results:

• Ineffective antigen retrieval (particularly important to follow the recommended TE buffer pH 9.0 or citrate buffer pH 6.0 protocols)

• Protein degradation during sample preparation

• Epitope masking due to protein-protein interactions

• Insufficient antibody concentration (below the recommended 1:500-1:2000 for WB or 1:750-1:3000 for IHC)

• Inadequate incubation time or temperature

To mitigate these issues, researchers should include appropriate positive controls (such as the validated cell lines K-562, Jurkat, A549, HeLa, or HepG2) and systematically optimize each step of their experimental protocol.

How can researchers distinguish between specific and non-specific bands in Western blot applications?

Distinguishing between specific and non-specific bands when using RPA3 antibody requires a systematic analytical approach:

• Molecular weight verification: The specific RPA3 band should appear at approximately 14 kDa, which is slightly higher than the calculated molecular weight of 13 kDa . Bands at significantly different molecular weights should be scrutinized as potential non-specific signals.

• Positive control comparison: Compare band patterns with those observed in validated positive control cell lines (K-562, Jurkat, A549, HeLa, or HepG2) . Consistent band patterns across controls and experimental samples increase confidence in specificity.

• Gradient analysis: If multiple bands are observed, perform a dilution series of the primary antibody. Specific bands typically maintain signal at higher dilutions while non-specific bands disappear more rapidly.

• Peptide competition: Pre-incubation of the antibody with the immunizing peptide should abolish specific bands while leaving non-specific bands unchanged.

• Knockdown/knockout validation: If possible, compare band patterns between wild-type samples and those with RPA3 knockdown or knockout to definitively identify the specific RPA3 band.

These approaches allow researchers to confidently identify the true RPA3 signal and avoid misinterpretation based on non-specific antibody binding.

How can RPA3 antibody contribute to understanding DNA damage response in single-cell analysis?

Single-cell analysis represents a frontier in understanding cellular heterogeneity within populations. RPA3 antibody can be leveraged in this context through several innovative approaches:

• Single-cell immunofluorescence: Using RPA3 antibody in multiplexed immunofluorescence can reveal cell-to-cell variation in RPA3 expression and localization, particularly in response to DNA damaging agents.

• Integration with single-cell sequencing: Correlating RPA3 protein expression patterns with single-cell transcriptomics or genomics can identify relationships between genetic variations (such as 53BP1 mutations) and RPA3 function.

• Spatial analysis in tissue contexts: Applying the validated IHC protocols in spatial transcriptomics or proteomics approaches can map RPA3 expression patterns relative to tissue architecture and microenvironmental features.

• Cell cycle-resolved analysis: Combining RPA3 antibody staining with cell cycle markers can reveal how RPA3 dynamics change throughout the cell cycle at the single-cell level.

• Real-time imaging in live cells: Correlating fixed-cell RPA3 antibody staining patterns with live-cell imaging of DNA damage markers can provide insights into the temporal dynamics of RPA3 recruitment to damage sites.

These applications extend beyond traditional bulk analyses to reveal nuanced aspects of RPA3 biology that may be masked in population averages.

What are the implications of RPA3 detection in cancer models with diverse genetic backgrounds?

The ability to detect and quantify RPA3 across cancer models with different genetic backgrounds has significant implications for cancer research and potential therapeutic approaches:

• Biomarker development: Patterns of RPA3 expression or localization may serve as biomarkers for specific genetic backgrounds, particularly in contexts involving DNA damage response pathway mutations such as those in TP53 or 53BP1 .

• Synthetic lethality screening: RPA3 detection can help identify contexts where inhibition of complementary DNA repair pathways might create synthetic lethality, similar to PARP inhibition in BRCA-deficient cancers.

• Tumor heterogeneity assessment: Using the validated IHC protocols , researchers can map RPA3 expression patterns across tumor sections to characterize intratumoral heterogeneity and its relationship to genetic subclones.

• Treatment response prediction: Monitoring changes in RPA3 expression or localization following treatment with DNA-damaging agents may help predict therapeutic response, particularly when combined with information about genetic background.

• Experimental design optimization: The single mouse experimental design approach enables testing of significantly more genetic backgrounds, potentially revealing context-specific roles for RPA3 that would be missed in more limited studies.

This broader perspective on RPA3 biology across diverse genetic contexts may ultimately contribute to more personalized approaches to cancer treatment based on DNA repair pathway status.